Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775265 · ClinicalTrials.gov registry record · Phase 3
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
A Phase 3 study of Muscle-Invasive Bladder Carcinoma and Bladder Urothelial Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 475
- Enrollment target
- 20
- Study locations
NCT03775265 is a Phase 3 study of Muscle-Invasive Bladder Carcinoma and Bladder Urothelial Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 475 participants, above the 92-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (416% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT03775265, a Phase 3 study of Muscle-Invasive Bladder Carcinoma and Bladder Urothelial Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 475 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- DRUG Atezolizumab
- DRUG Cisplatin
- PROCEDURE Cystoscopy
- PROCEDURE Biopsy of Bladder
Study Locations (20)
California
- Sutter Auburn Faith Hospital - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Mercy Cancer Center - Elk Grove - Elk Grove
- UC San Diego Moores Cancer Center - La Jolla
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Fremont - Rideout Cancer Center - Marysville
- Memorial Medical Center - Modesto
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Palo Alto Medical Foundation Health Care - Palo Alto
- Mercy Cancer Center - Rocklin - Rocklin
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03775265
The ClinicalTrials.gov registry entry for NCT03775265 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (416% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT03775265 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03775265 about?
NCT03775265 is a clinical study titled "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer". This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cispl...
What is the current status of trial NCT03775265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 475 participants. The study started on 2019-06-03. Estimated completion is 2027-06-01.
What conditions does trial NCT03775265 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8.
What interventions are being tested in trial NCT03775265?
The interventions under investigation include: Computed Tomography (PROCEDURE), Atezolizumab (DRUG), Cisplatin (DRUG), Cystoscopy (PROCEDURE), Biopsy of Bladder (PROCEDURE).
Who is sponsoring clinical trial NCT03775265?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03775265 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylactic Antibiotics in Cystectomy With Diversion
RECRUITING · Early Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
RECRUITING · NA
-
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.